

ASX ANNOUNCEMENT

Benitec Biopharma to present this week at San Jose Pain Therapeutics Summit and San Francisco Investor Forum

Sydney, October 2, 2012: Benitec Biopharma announced today that it will present scientific and commercial updates at two conferences in California this week.

Benitec Biopharma's Chief Scientist Dr Michael Graham will provide an update on the progress of the Company's Neuropathic Pain Program at the *6th Annual Pain Therapeutics Summit* to be held in San Jose, California, on October 3-4, 2012. The title of Dr Graham's presentation, scheduled for the morning of the opening day is: **Gene Therapy to Control Intractable Pain in Cancer Patients: A New Paradigm?** The Summit is the USA's premier conference in the field of pain management and therapeutics. It brings together key industry leaders and academic researchers to discuss topics ranging from cutting-edge drug discovery science to new therapies and products. Benitec Biopharma's ddRNAi-based program represents a novel approach to treatment of intractable cancer-associated pain, and it is being progressed under a contractual agreement with Stanford University.

On October 9th, Benitec Biopharma's Chief Business Officer, Mr. Carl Stubbings, will present the Company's commercial and clinical development strategy at the *11th BIO Investor Forum* in San Francisco. The Annual BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies.

Dr Peter French, Benitec Biopharma's CEO, said, "With both Dr Graham and Mr. Stubbings attending these prestigious meetings, it is our aim to raise the Company's profile both scientifically and commercially in the US, by demonstrating the potential of our ddRNAi technology to develop novel therapeutics for significant human health conditions. They will take advantage of the opportunity to meet with key stakeholders in the US to provide updates on Benitec Biopharma's progress in advancing our technology to the clinic and the Company's commercial strategy."

About Benitec Biopharma Limited

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), also called expressed RNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as cancer-associated pain, Hepatitis C, drug resistant lung cancer and OPMD based on this technology.

For more information please contact:

Dr Peter French | Chief Executive Officer

Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com